Management of Hyperkalemia in Patients Taking Lisinopril

Classification and Risk Assessment

Hyperkalemia can be classified as mild (>5.0 to <5.5 mEq/L), moderate (5.5 to 6.0 mEq/L), or severe (>6.0 mEq/L) 3, 4
Risk factors for hyperkalemia in patients on lisinopril include: chronic kidney disease, diabetes mellitus, heart failure, advanced age, and concomitant use of potassium-sparing diuretics, potassium supplements, or NSAIDs 6

For severe hyperkalemia (>6.0 mEq/L) or with ECG changes, administer IV calcium gluconate or calcium chloride to protect cardiac tissue (acts within 1-3 minutes) 7, 4
Administer IV insulin (10 units) with glucose (50 ml of 50% solution) to shift potassium intracellularly 8, 3
Consider inhaled beta-agonists (e.g., salbutamol) to shift potassium intracellularly 7, 3
Use loop diuretics to increase renal potassium excretion 3, 7
Consider hemodialysis in severe cases unresponsive to other measures 7
Use potassium binders (sodium polystyrene sulfonate, patiromer, or sodium zirconium cyclosilicate) to eliminate potassium 3, 4

The American Heart Association recommends adding an SGLT2 inhibitor while continuing lisinopril to reduce the risk of serious hyperkalemia (HR 0.84; 95% CI, 0.76-0.93) in patients taking RAAS inhibitors 1, 2
Consider switching to sacubitril/valsartan in patients with heart failure to reduce the risk of severe hyperkalemia (HR 1.37; 95% CI, 1.06-1.76 for enalapril vs. sacubitril/valsartan) 2, 1
Use potassium binders, such as patiromer, to lower rates of hyperkalemia (HR 0.63; 95% CI, 0.45-0.87) compared to placebo when used with high-dose RAAS inhibitors 1, 2
Consider reducing lisinopril dose rather than discontinuation to maintain cardiovascular and renal benefits of RAAS inhibition while reducing hyperkalemia risk 10, 2

Monitor serum potassium and renal function within 1-2 weeks of initiating lisinopril, with each dose increase, and at least yearly, as recommended by the American Geriatrics Society 11
For high-risk patients (CKD, diabetes, heart failure), check potassium levels more frequently (7-10 days after starting or increasing lisinopril) 7, 8
Discontinue potassium supplements and counsel patients to avoid high-potassium foods and NSAIDs, as advised by the American Heart Association 9
Consider loop diuretics rather than potassium-sparing diuretics in patients with hyperkalemia risk, as recommended by the European Heart Journal 9, 3

Patients with advanced CKD may tolerate slightly higher potassium levels (optimal range 3.3-5.5 mEq/L in CKD stages 4-5), according to the Mayo Clinic Proceedings 6, 4
Hyperkalemia can rarely cause paralysis and other severe non-cardiac complications, as reported in the Mayo Clinic Proceedings 7

Discontinuing lisinopril completely rather than adjusting the dose or adding an SGLT2 inhibitor, as cautioned by the American Journal of Kidney Diseases 1, 10
Failing to monitor potassium levels after initiating or increasing lisinopril dose, as warned by the Journal of the American Geriatrics Society 11, 8
Underestimating the importance of maintaining RAAS inhibition for cardiovascular and renal protection despite hyperkalemia risk, as emphasized by the European Heart Journal 10, 2